8x8 Issued New Contact Center Patent By U.S. Patent And Trademark Office

8x8, Inc. (NASDAQ: EGHT), provider of innovative cloud communications and computing solutions, today announced that it has been awarded a new patent related to its contact center technologies. On June 18, 2013, the U.S. Patent and Trademark Office issued United States Patent number 8,468,545 entitled “Interaction Management.”

This patent relates generally to methods and systems for managing networked contact centers and, more specifically, for a networked call center that integrates disparate call center resources.

Since its establishment in 1987, 8x8 has been awarded eighty-eight (88) United States patents covering a variety of voice and video communications, signaling, processing and storage technologies.

About 8x8, Inc.

8x8, Inc. (NASDAQ: EGHT) empowers business conversations for more than 30,000 small and medium-sized businesses with cloud communications services that include hosted PBX telephony, unified communications, call center software and video conferencing solutions. The company has been delivering business communications services since 2004 and has garnered a reputation for technical excellence and outstanding reliability. In 2012, 8x8 was named a market “leader” in Gartner’s Magic Quadrant for Unified Communications as a Service (UCaaS) in North America and was recognized as the No. 1 Provider of Hosted IP Telephony by Frost & Sullivan and Synergy Research Group. For additional information, visit  www.8x8.com, or connect with 8x8 on Google+, Facebook, LinkedIn and Twitter.

Copyright Business Wire 2010

If you liked this article you might like

My Market Scans are Unimpressive

My Market Scans are Unimpressive

8x8 (EGHT) Stock Rises on Q1 Earnings Beat

8x8 (EGHT) Stock Rises on Q1 Earnings Beat

8x8 (EGHT): Today's Weak On High Volume Stock

8x8 (EGHT): Today's Weak On High Volume Stock

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan

'Mad Money' Lightning Round: Buy, Buy, Buy Seres Therapeutics

'Mad Money' Lightning Round: Buy, Buy, Buy Seres Therapeutics